Improving the design and analysis of drug efficacy/effectiveness studies in malaria and in selected neglected tropical diseases (NTDs).

改进疟疾和选定的被忽视热带病（NTD）药物疗效/有效性研究的设计和分析。

• 批准号: MR/L022508/1
• 负责人: Ian Hastings
• 金额: $ 40.25万
• 依托单位: Liverpool School of Tropical Medicine
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FL022508%2F1
• 关键词: Improving; design; analysis; drug; efficacy

Infectious tropical diseases place an enormous burden on many human populations. The vast majority of such infections can be successfully treated and/or controlled by drugs so the continued provision of effective drugs is an essential component of medical provision in these settings. Such studies often take place in areas where mobile human populations and poor infrastructure mean that patient follow-up is challenging and often incomplete, and where high re-infection rates often obscure successful treatment outcomes. We argue that current methods of measuring drug efficacy/effectiveness in these settings could clearly be improved in a number of areas. We start by investigating an important paradigm species, falciparum malaria, which is one of the 'big three' infective killers, and then move onto the so-called 'neglected tropical diseases' with initial emphasis on shistosomes (a 'worm' infection spread by contact with water containing the snail intermediate hosts). We also consider how information on drug efficacy/effectiveness can be obtained from studies outside of formal drug clinical trials, such such as intermittent treatment programmes.

热带传染病给许多人带来了巨大的负担。绝大多数这类感染可以通过药物成功地治疗和/或控制，因此继续提供有效药物是在这些环境中提供医疗服务的一个重要组成部分。这类研究经常在人口流动和基础设施差的地区进行，这意味着患者的随访具有挑战性，而且往往不完整，而且高再感染率往往掩盖了成功的治疗结果。我们认为，目前在这些环境中衡量药物效力/有效性的方法显然可以在一些领域得到改进。我们首先研究一种重要的范例物种--恶性疟，它是感染性三大杀手之一，然后转到所谓的被忽视的热带疾病，最初重点是血吸虫(一种通过接触含有蜗牛中间宿主的水传播的‘蠕虫’感染)。我们亦会考虑如何从正式药物临床试验以外的研究，例如间歇治疗计划，取得有关药物效力/效用的资料。

项目成果

Quantifying the pharmacology of antimalarial drug combination therapy.

• DOI: 10.1038/srep32762
• 发表时间: 2016-09-08
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Hastings IM;Hodel EM;Kay K
• 通讯作者: Kay K

Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough?

• DOI: 10.1186/1475-2875-13-62
• 发表时间: 2014-02-20
• 期刊: Malaria journal
• 影响因子: 3
• 作者: Hastings IM;Hodel EM
• 通讯作者: Hodel EM

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.

• DOI: 10.1186/1475-2875-13-138
• 发表时间: 2014-04-07
• 期刊: Malaria journal
• 影响因子: 3
• 作者: Hodel EM;Kay K;Hayes DJ;Terlouw DJ;Hastings IM
• 通讯作者: Hastings IM

Incorporating genetic selection into individual-based models (IBMs) of malaria and other infectious diseases

将遗传选择纳入疟疾和其他传染病的个体模型 (IBM)

• DOI: 10.1101/819367
• 发表时间: 2019
• 作者: Hastings I

How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

• DOI: 10.1128/aac.00481-15
• 发表时间: 2015-10-01
• 期刊: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
• 影响因子: 4.9
• 作者: Hastings, Ian M.;Kay, Katherine;Hodel, Eva Maria
• 通讯作者: Hodel, Eva Maria